| Cell Line | Donor Age | Sex | Race | Disease | Tumor type | Anatomical site | Cell Characateristics | Missense Mutation - KRAS | Missense Mutation - TP53 | Missense Mutation - CDKN2A | Missense Mutation - SMAD4 | hidden | hidden |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PATU8988S | 64.0 | Female | White | PDAC | Metastatic | Liver | Adherent epitheloid cells in monolayer | G12V | R282W | No | No | G12 | Yes |
| PATU8988T | 64.0 | Female | White | PDAC | Metastatic | Liver | NA | G12V | R282W | No | No | G12 | Yes |
| PANC0213 | 64.0 | Female | White | Adenocarcinoma, NOS | Primary | Pancreas | NA | Q61R | R273C | No | No | Q61 | Yes |
| PANC0203 | 70.0 | Female | White | Adenocarcinoma, NOS | Primary | Pancreas | Adherent | G12D | R248Q | No | No | G12 | Yes |
| PANC1005 | 81.0 | Male | White | PDAC | Primary | Pancreas | NA | No | I255N | No | No | No | Yes |
| T3M4 | 64.0 | Male | Asian | PDAC | Primary | Lymph node | Adherent | Q61H | Y220C | No | No | Q61 | Yes |
| PANC0504 | 77.0 | Female | White | Adenocarcinoma, NOS | Primary | Pancreas | Adherent | G12D | No | No | No | G12 | No |
| HPAFII | 44.0 | Male | White | PDAC | Metastatic | Ascites | Adherent epithelial | G12D | P151S | No | No | G12 | Yes |
| CAPAN2 | 56.0 | Male | White | PDAC | Primary | Pancreas | NA | G12V | No | No | No | G12 | No |
| KP3 | 75.0 | Male | Asian | Adenosquamous carcinoma | Metastatic | Liver | Epithelial-like | G12V | No | No | No | G12 | No |
| SU8686 | 57.0 | Female | White | PDAC | Metastatic | Liver | NA | G12D | G360V,G245S | No | No | G12 | Yes |
| HUPT3 | 66.0 | Male | Asian | Adenocarcinoma, NOS | Metastatic | Ascites | Adherent | G12R | R282W | No | No | G12 | Yes |
| CFPAC1 | 26.0 | Male | White | PDAC | Metastatic | Liver | Mixed | G12V | C242R | No | No | G12 | Yes |
| PANC0327 | 65.0 | Female | White | PDAC | Primary | Pancreas | Adherent epithelial | G12V | No | No | No | G12 | No |
| SW1990 | 56.0 | Male | White | PDAC | Primary | Spleen | NA | G12D | No | No | No | G12 | No |
| PANC1 | 56.0 | Male | White | PDAC | Primary | Pancreas | NA | G12D | R273H | No | No | G12 | Yes |
| HS766T | 64.0 | Male | White | PDAC | Metastatic | Lymph node | NA | Q61H | No | No | No | Q61 | No |
| PK59 | 66.0 | Female | Asian | Adenocarcinoma, NOS | Metastatic | Liver | Epithelial-like | G12D | No | No | No | G12 | No |
| HUPT4 | 60.0 | Male | Asian | Adenocarcinoma, NOS | Metastatic | Ascites | Mixed | G12V | I255T | No | No | G12 | Yes |
| ASPC1 | 62.0 | Female | White | PDAC | Metastatic | Ascites | Adherent | G12D | No | No | R100T | G12 | No |
| PANC0403 | 70.0 | Male | White | Adenocarcinoma, NOS | Primary | Pancreas | Adherent epithelial | G12D | G245S | No | No | G12 | Yes |
| DANG | 68.0 | Female | White | Adenocarcinoma, NOS | NA | Pancreas | Adherent epitheloid cells in monolayer | G12V | No | No | No | G12 | No |
| KP4 | 50.0 | Male | Asian | PDAC | Metastatic | Ascites | Adherent | G12D | No | No | No | G12 | No |
| SNU213 | 65.0 | Male | Asian | Adenocarcinoma, NOS | NA | Pancreas | Epithelial; monolayer | G12V | S215I | A20P | D319E | G12 | Yes |
| HPAC | 64.0 | Female | White | PDAC | Primary | Pancreas | Adherent epithelial | G12D | No | No | No | G12 | No |
| KP2 | 65.0 | Female | Asian | Adenocarcinoma, NOS | Primary | Pancreas | NA | G12R | A161D | No | No | G12 | Yes |
| PK1 | NA | Male | Asian | Adenocarcinoma, NOS | Metastatic | Liver | Adherent | G12D | M237I | No | No | G12 | Yes |
| PSN1 | 36.0 | Male | Asian | PDAC | Primary | Pancreas | Adherent epithelial | G12R | K132Q | No | No | G12 | Yes |
| YAPC | 43.0 | Male | Asian | Adenocarcinoma, NOS | Metastatic | Ascites | Adherent | G12V | H179R | No | No | G12 | Yes |
| QGP1 | 61.0 | Male | Asian | PNET | Primary | Pancreas | Adherent epithelial | G12V | No | No | No | G12 | No |
| CAPAN1 | 40.0 | Male | White | PDAC | Metastatic | Liver | Adherent | G12V | A159V | No | No | G12 | Yes |
| PANC0813 | 85.0 | Male | White | PDAC | Primary | Pancreas | NA | G12D | No | No | No | G12 | No |
| PK45H | NA | NA | Asian | Adenocarcinoma, NOS | Primary | Pancreas | Adherent | G12D | No | No | No | G12 | No |
| TCCPAN2 | 47.0 | Female | Asian | Adenocarcinoma, NOS | Metastatic | Ascites | Adherent epithelial | G12R | No | No | No | G12 | No |
| SNU410 | 53.0 | Male | Asian | Adenocarcinoma, NOS | Metastatic | Liver | Epithelial; monolayer | G12D | S127F | No | No | G12 | Yes |
| BXPC3 | 61.0 | Female | White | PDAC | Primary | Pancreas | NA | No | Y220C | No | No | No | Yes |
| PATU8902 | 44.0 | Female | White | PDAC | Primary | Pancreas | Adherent epitheloid cells in monolayer | G12V | C176S | No | No | G12 | Yes |
| MIAPACA2 | 65.0 | Male | White | PDAC | Primary | Pancreas | NA | G12C | R248W | No | No | G12 | Yes |
| SUIT2 | 73.0 | Male | Asian | PDAC | Metastatic | Liver | Adherent epithelial-like | G12D | R273H | No | No | G12 | Yes |
| L33 | 77.0 | Female | Black/African-American | Adenosquamous carcinoma | Metastatic | Lymph node | Adherent | G12D | No | No | P260L | G12 | No |
| SNU324 | 50.0 | Male | Asian | Adenocarcinoma, NOS | NA | Pancreas | Epithelial; monolayer | No | No | D23P | No | No | No |
| GRM | 36.0 | Male | Asian | Adenocarcinoma, NOS | Primary | Pancreas | NA | No | No | No | No | No | No |
| KCIMOH1 | 64.0 | Female | White | PDAC | Primary | Pancreas | NA | G12D | No | No | No | G12 | No |
| KLM1 | NA | Male | Asian | PDAC | Metastatic | Liver | NA | No | No | No | No | No | No |
| KP1N | 56.0 | Male | White | PDAC | Primary | Pancreas | NA | G12D | R273H | No | No | G12 | Yes |
| PL45 | 81.0 | Male | White | PDAC | NA | Pancreas | NA | No | No | No | No | No | No |
| JOPACA1 | 46.0 | Male | NA | Adenocarcinoma, NOS | Primary | Pancreas | NA | G12V | No | No | No | G12 | No |
| PACADD119 | 59.0 | Male | NA | Adenocarcinoma, NOS | Primary | Pancreas | NA | G12A | C238Y | No | No | G12 | Yes |
| PACADD135 | 48.0 | Female | NA | Adenocarcinoma, NOS | Metastatic | Lymph node | NA | G12V | No | No | No | G12 | No |
| PACADD137 | 75.0 | Female | NA | Adenocarcinoma, NOS | Primary | Pancreas | NA | No | No | No | No | No | No |
| PACADD159 | 78.0 | Male | NA | Adenocarcinoma, NOS | Primary | Pancreas | NA | G12I | No | No | No | G12 | No |
| PACADD161 | 63.0 | Female | NA | Adenocarcinoma, NOS | Metastatic | Liver | NA | G12V | No | No | No | G12 | No |
| PACADD165 | 54.0 | Male | NA | Adenocarcinoma, NOS | Metastatic | Ascites | NA | No | F113S | No | No | No | Yes |
| PACADD188 | 68.0 | Female | NA | Adenocarcinoma, NOS | Metastatic | Pancreas | NA | G12D | No | No | No | G12 | No |
| 9505BIK | NA | Male | NA | Adenocarcinoma, NOS | NA | Pancreas | NA | G12V | R273C | No | No | G12 | Yes |
| PK8 | NA | NA | NA | Adenocarcinoma, NOS | Metastatic | Liver | NA | G12R | No | No | No | G12 | No |
| MZ1PC | 46.0 | Male | NA | Adenocarcinoma, NOS | Metastatic | Pancreas | NA | G12V | No | No | No | G12 | No |
| PL18 | NA | NA | NA | Adenocarcinoma, NOS | NA | Pancreas | NA | No | R267W | H15R | No | No | Yes |
| PL4 | NA | NA | NA | Adenocarcinoma, NOS | NA | Pancreas | NA | G12D | G266V | No | No | G12 | Yes |
| MAPACHS77 | 64.0 | Male | NA | Adenocarcinoma, NOS | NA | Pancreas | NA | G12V | A159D | No | No | G12 | Yes |
Overview
Patient Statistics
Tumour Statistics
Tumor Type
Missense Mutation - KRAS
Cohort Summary
Variant Identification
Drug Prediction
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| ERBB3 | V104L | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | V104L | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| KRAS | G12V | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12V | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12V | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12V | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12V | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12V | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12V | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12V | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12V | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12V | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12V | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12V | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12V | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12V | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12V | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12V | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12V | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12V | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12V | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12V | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12V | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12V | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12V | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12V | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12V | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12V | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| TP53 | R273C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | L3221P | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | L3221P | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | L3221P | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | L3221P | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | L3221P | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | L3221P | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | D1843Y | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRD4 | P1012P | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| GNAS | R201H | Complete Match | JAK inhibitor | Responsive | CANCER | Pre-clinical |
| KRAS | G12D | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12D | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12D | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12D | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12D | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12D | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12D | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12D | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12D | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12D | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12D | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12D | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12D | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12D | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12D | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12D | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12D | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12D | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12D | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12D | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12D | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12D | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12D | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12D | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12D | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12D | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12D | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| FBXW7 | R465C | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | R465C | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | R465C | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | R465C | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| RNF43 | S720* | Complete Match | Porcupine inhibitor | Responsive | COREAD | Case report |
| KMT2A | P3539H | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | P3539H | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | P3539H | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | P3539H | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | P3539H | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | P3539H | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ALK | G1202G | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G1202G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | G1202G | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | G1202G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | G1202G | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | G1202G | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | G1202G | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | G1202G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | G1202G | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | G1202G | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | G1202G | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | G1202G | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | G1202G | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G1202G | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G1202G | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | G1202G | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | G1202G | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | G1202G | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | G1202G | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | Y220C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y220C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y220C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y220C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y220C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y220C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y220C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y220C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y220C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y220C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRD4 | S796* | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ESR1 | S106G | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| FANCA | E1196* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Case report |
| FANCA | E1196* | Different Alteration | Olaparib (PARP inhibitor) | Responsive | PRAD | Case report |
| TP53 | A159V | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | A159V | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | A159V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | A159V | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | A159V | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | A159V | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | A159V | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A159V | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A159V | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | A159V | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | A159V | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | A159V | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A159V | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | A159V | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A159V | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | R309G | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | R309G | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ABL1 | G1060D | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | G1060D | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | G1060D | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | G1060D | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | G1060D | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | G1060D | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | T125T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | T125T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | T125T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | T125T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | T125T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | T125T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | T125T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T125T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T125T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | T125T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | T125T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | T125T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T125T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | T125T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T125T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | T490M | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | T490M | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | T490M | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH1 | A811A | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | A811A | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRD4 | H829P | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| TP53 | C242R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C242R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C242R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C242R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C242R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C242R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C242R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C242R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C242R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C242R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C242R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C242R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C242R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C242R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C242R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| AKT3 | R241Q | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | G187R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G187R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G187R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G187R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G187R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G187R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G187R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G187R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G187R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G187R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G187R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G187R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G187R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G187R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G187R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDKN2A | E120* | Complete Match | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | E120* | Complete Match | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | E120* | Complete Match | CDK4/6 inhibitor | Responsive | CM | Case report |
| CDKN2A | E120* | Complete Match | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | E120* | Different Alteration | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | E120* | Different Alteration | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | E120* | Different Alteration | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | E120* | Different Alteration | CDK4/6 inhibitor | Responsive | CM | Case report |
| TP53 | P151S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P151S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P151S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P151S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P151S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P151S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P151S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P151S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P151S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P151S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P151S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P151S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P151S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P151S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P151S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RNF43 | E174* | Complete Match | Porcupine inhibitor | Responsive | COREAD | Case report |
| BRD4 | V242V), BRD4 MUT* (P243P | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ARID1A | Q538* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q538* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q538* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q538* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ABL1 | R589H | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | R589H | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | R589H | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | R589H | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | R589H | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | R589H | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| KRAS | Q61H | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | Q61H | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | Q61H | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | Q61H | Different Mutation | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | Q61H | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | Q61H | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | Q61H | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | Q61H | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61H | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | Q61H | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | Q61H | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | Q61H | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61H | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | Q61H | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61H | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | Q61H | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61H | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | Q61H | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | Q61H | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | Q61H | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61H | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | Q61H | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61H | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | Q61H | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | Q61H | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | Q61H | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | Q61H | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | Q61H | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | Q61H | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | Q61H | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | Q61H | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61H | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | Q61H | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61H | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61H | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | Q61H | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61H | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | Q61H | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | Q61H | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | Q61H | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | Q61H | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | Q61H | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| CDKN2A | splice_donor_variant | Complete Match | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | splice_donor_variant | Complete Match | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | splice_donor_variant | Complete Match | CDK4/6 inhibitor | Responsive | CM | Case report |
| CDKN2A | splice_donor_variant | Complete Match | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | splice_donor_variant | Different Alteration | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | splice_donor_variant | Different Alteration | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | splice_donor_variant | Different Alteration | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | splice_donor_variant | Different Alteration | CDK4/6 inhibitor | Responsive | CM | Case report |
| KMT2A | M472I | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | M472I | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | M472I | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | M472I | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | M472I | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | M472I | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| KRAS | G12R | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12R | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12R | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12R | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12R | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12R | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12R | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12R | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12R | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12R | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12R | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12R | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12R | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12R | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12R | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12R | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12R | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12R | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12R | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12R | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12R | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12R | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12R | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12R | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12R | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12R | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12R | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12R | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12R | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12R | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12R | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12R | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12R | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12R | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12R | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12R | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12R | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12R | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12R | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| TP53 | R282W | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R282W | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R282W | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R282W | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R282W | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R282W | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R282W | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R282W | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R282W | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R282W | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R282W | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R282W | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R282W | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R282W | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R282W | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | M636V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NOTCH2 | A21S | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | A21S | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | A21S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | I255T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I255T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | I255T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | I255T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | I255T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | I255T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I255T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | I255T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | I255T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | I255T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | I255T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | M288R | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | M288R | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | M288R | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | M288R | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | M288R | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | M288R | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| TP53 | splice_donor_variant | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | splice_donor_variant | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | splice_donor_variant | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | splice_donor_variant | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | splice_donor_variant | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | splice_donor_variant | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | splice_donor_variant | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | splice_donor_variant | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | splice_donor_variant | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273H | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273H | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273H | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273H | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273H | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273H | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273H | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273H | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273H | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273H | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273H | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273H | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | M1478T | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M1478T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | M1478T | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | M1478T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | M1478T | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | M1478T | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | M1478T | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | M1478T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | M1478T | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | M1478T | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | M1478T | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | M1478T | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | M1478T | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M1478T | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M1478T | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | M1478T | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | M1478T | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | M1478T | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | M1478T | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | A161D | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | A161D | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | A161D | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | A161D | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | A161D | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | A161D | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | A161D | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A161D | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A161D | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | A161D | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | A161D | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | A161D | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A161D | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | A161D | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A161D | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CRLF2 | P224L | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | P224L | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH2 | H2194H | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PTCH1 | Q938* | Complete Match | Vismodegib (SHH inhibitor) | Responsive | BCC, MB | FDA guidelines |
| PTCH1 | Q938* | Complete Match | Foretinib (MET inhibitor) | Responsive | MB | Pre-clinical |
| PTCH1 | Q938* | Complete Match | SMO inhibitor | Responsive | MB | Pre-clinical |
| TP53 | A159D | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | A159D | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | A159D | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | A159D | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | A159D | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | A159D | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | A159D | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A159D | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A159D | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | A159D | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | A159D | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | A159D | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A159D | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | A159D | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A159D | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ARID1A | Q321* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q321* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q321* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q321* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| KRAS | G12C | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12C | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12C | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12C | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12C | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12C | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12C | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12C | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12C | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12C | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12C | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12C | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12C | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12C | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12C | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12C | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12C | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12C | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12C | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12C | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12C | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12C | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12C | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12C | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12C | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12C | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| TP53 | R248W | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248W | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248W | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248W | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248W | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248W | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248W | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248W | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248W | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248W | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248W | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248W | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | L2457V | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | L2457V | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BCR | R22L | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | R22L | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | R22L | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | R22L | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | R22L | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | R22L | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| CDKN2A | R80* | Complete Match | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | R80* | Complete Match | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | R80* | Complete Match | CDK4/6 inhibitor | Responsive | CM | Case report |
| CDKN2A | R80* | Complete Match | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | R80* | Different Alteration | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | R80* | Different Alteration | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | R80* | Different Alteration | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | R80* | Different Alteration | CDK4/6 inhibitor | Responsive | CM | Case report |
| KMT2D | C5123* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | LUSC | Pre-clinical |
| KMT2A | G3884F | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | G3884F | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | G3884F | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | G3884F | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | G3884F | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | G3884F | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| KRAS | G12A | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12A | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12A | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12A | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12A | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12A | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12A | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12A | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12A | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12A | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12A | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12A | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12A | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12A | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12A | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12A | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12A | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12A | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12A | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12A | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12A | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12A | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12A | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12A | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12A | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12A | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12A | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12A | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12A | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12A | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12A | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12A | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12A | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12A | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12A | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12A | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12A | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12A | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12A | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12A | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12A | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12A | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| TP53 | C238Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C238Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C238Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C238Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C238Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C238Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C238Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C238Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C238Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C238Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C238Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C238Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C238Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C238Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C238Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RET | P684P | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | P684P | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | P684P | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | P684P | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | P684P | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | P684P | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | P684P | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | P684P | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | P684P | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| CHEK2 | splice_donor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| CHEK2 | splice_donor_variant | Different Alteration | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| PML | A93G | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | A93G | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | A93G | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| FGFR2 | G131R | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | G131R | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| KMT2A | L3462P), MLL MUT* (I2918V | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | L3462P), MLL MUT* (I2918V | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | L3462P), MLL MUT* (I2918V | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | L3462P), MLL MUT* (I2918V | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | L3462P), MLL MUT* (I2918V | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | L3462P), MLL MUT* (I2918V | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| BCR | F1148F), BCR MUT* (G187G | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | F1148F), BCR MUT* (G187G | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | F1148F), BCR MUT* (G187G | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | F1148F), BCR MUT* (G187G | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | F1148F), BCR MUT* (G187G | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | F1148F), BCR MUT* (G187G | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| KRAS | G12I | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12I | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12I | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12I | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12I | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12I | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12I | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12I | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12I | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12I | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12I | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12I | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12I | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12I | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12I | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12I | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12I | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12I | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12I | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12I | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12I | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12I | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12I | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12I | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12I | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12I | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12I | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12I | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12I | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12I | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12I | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12I | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12I | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12I | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12I | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12I | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12I | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12I | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12I | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12I | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12I | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| ARID1A | Q503* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q503* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q503* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q503* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R306* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R306* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R306* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R306* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R306* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R306* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R306* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R306* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R306* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R306* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R306* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R306* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R306* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R306* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R306* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | Y2619C | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | Y2619C | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | Y2619C | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | Y2619C | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | Y2619C | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | Y2619C | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| IDH1 | R132L | Complete Match | Venetoclax (BCL2 inhibitor) | Responsive | AML | Early trials |
| IDH1 | R132L | Complete Match | IDH1 inhibitor | Responsive | AML | Early trials |
| IDH1 | R132L | Complete Match | AG-120 (IDH1 inhibitor) | Responsive | G | Early trials |
| IDH1 | R132L | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | CH | Early trials |
| IDH1 | R132L | Complete Match | Ivosidenib (IDH1 inhibitor) | Responsive | AML | Early trials |
| IDH1 | R132L | Complete Match | BCL2 inhibitor | Responsive | AML | Pre-clinical |
| IDH1 | R132L | Complete Match | BCL2 inhibitor (BCL2 inhibitor) | Responsive | AML | Pre-clinical |
| IDH1 | R132L | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | BT | Pre-clinical |
| IDH1 | R132L | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| PBRM1 | S1500* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | R | Pre-clinical |
| PBRM1 | S1500* | Complete Match | anti-PD1 inhibitor | Responsive | RCCC | Early trials |
| PBRM1 | S1500* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RCC | Early trials |
| PBRM1 | S1500* | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| PBRM1 | S1500* | Different Alteration | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| ROS1 | R1942W | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | R1942W | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | R1942W | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | R1942W | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | R1942W | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH1 | T518M | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | T518M | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | R248Q | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KRAS | Q61R | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | Q61R | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | Q61R | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | Q61R | Different Mutation | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | Q61R | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | Q61R | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | Q61R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | Q61R | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | Q61R | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | Q61R | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | Q61R | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61R | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | Q61R | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61R | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | Q61R | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61R | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | Q61R | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | Q61R | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | Q61R | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61R | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | Q61R | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61R | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | Q61R | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | Q61R | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | Q61R | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | Q61R | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | Q61R | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | Q61R | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | Q61R | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | Q61R | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61R | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | Q61R | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | Q61R | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61R | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | Q61R | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | Q61R | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | Q61R | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | Q61R | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | Q61R | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | Q61R | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | Q61R | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| NTRK1 | R119R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | R119R | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | R119R | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | R119R | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TMPRSS2 | E297K | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | E297K | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| TP53 | G245S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G245S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G245S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G245S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G245S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G245S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G245S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G245S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G245S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G245S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G245S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G245S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G245S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G245S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G245S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | F200S | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | F200S | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | F200S | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH2 | T43S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | E322K | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | E322K | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | E322K | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| LRP1B | E3875* | Complete Match | Liposomal Doxorubicin (Chemotherapy) | Resistant | OV | Early trials |
| LRP1B | E3875* | Different Alteration | Liposomal Doxorubicin (Chemotherapy) | Resistant | OV | Early trials |
| PBRM1 | R534* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | R | Pre-clinical |
| PBRM1 | R534* | Complete Match | anti-PD1 inhibitor | Responsive | RCCC | Early trials |
| PBRM1 | R534* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RCC | Early trials |
| PBRM1 | R534* | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| PBRM1 | R534* | Different Alteration | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I255N | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I255N | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | I255N | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | I255N | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | I255N | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | I255N | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I255N | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255N | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255N | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | I255N | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | I255N | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | I255N | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255N | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | I255N | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255N | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EPHA3 | C306* | Different Alteration | EPHA3 inhibitor | Responsive | CANCER | Pre-clinical |
| FGFR3 | V393V | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | V393V | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | V393V | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| TP53 | C176S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C176S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C176S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C176S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C176S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C176S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C176S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C176S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C176S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C176S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C176S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C176S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C176S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C176S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C176S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | G438G | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRD4 | P267P | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ERBB4 | C156C | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | M237I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | M237I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | M237I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | M237I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | M237I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | M237I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | M237I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M237I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M237I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | M237I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | M237I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | M237I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M237I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | M237I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M237I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | I681N | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| EGFR | W1157C | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | W1157C | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ALK | P1112P | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | P1112P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | P1112P | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | P1112P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | P1112P | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | P1112P | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | P1112P | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | P1112P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | P1112P | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | P1112P | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | P1112P | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | P1112P | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | P1112P | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | P1112P | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | P1112P | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | P1112P | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | P1112P | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | P1112P | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | P1112P | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| JAK3 | Q501H | Complete Match | JAK inhibitor | Responsive | MKB | Pre-clinical |
| JAK3 | Q501H | Different Mutation | JAK inhibitor | Responsive | LY | Pre-clinical |
| PBRM1 | Y387* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | R | Pre-clinical |
| PBRM1 | Y387* | Complete Match | anti-PD1 inhibitor | Responsive | RCCC | Early trials |
| PBRM1 | Y387* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RCC | Early trials |
| PBRM1 | Y387* | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| PBRM1 | Y387* | Different Alteration | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q167* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q167* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q167* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q167* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q167* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q167* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q167* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q167* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q167* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q167* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q167* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q167* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q167* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q167* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q167* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | P2216L | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | P2216L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| FGFR2 | F646V | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | F646V | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | R267W | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R267W | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R267W | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R267W | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R267W | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R267W | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R267W | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R267W | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R267W | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R267W | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R267W | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R267W | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R267W | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R267W | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R267W | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | G266V | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G266V | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G266V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G266V | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G266V | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G266V | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G266V | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G266V | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G266V | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G266V | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G266V | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G266V | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G266V | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G266V | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G266V | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | P1365L | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | P1365L | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | P1365L | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | P1365L | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | P1365L | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | P1365L | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ARID1A | splice_donor_variant | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | P281L | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | PA | Case report |
| STK11 | P281L | Complete Match | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | P281L | Complete Match | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | P281L | Complete Match | BET inhibitor | Resistant | L | Pre-clinical |
| STK11 | P281L | Complete Match | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | P281L | Complete Match | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | P281L | Complete Match | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | P281L | Different Alteration | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | P281L | Different Alteration | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | P281L | Different Alteration | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | P281L | Different Alteration | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | P281L | Different Alteration | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | P281L), KRAS MUT (G12R | Complete Match | MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) | Resistant | LUAD | Pre-clinical |
| STK11 | P281L), KRAS MUT (G12R | Complete Match | PD1 Ab inhibitor | Resistant | LUAD | Early trials |
| STK11 | P281L), KRAS MUT (G12R | Different Alteration | PD1 Ab inhibitor | Resistant | LUAD | Early trials |
| STK11 | P281L), KRAS MUT (G12R | Different Alteration | MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) | Resistant | LUAD | Pre-clinical |
| FGFR2 | P814T | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | P814T | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | K132Q | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | K132Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | K132Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | K132Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | K132Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | K132Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | K132Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | K132Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | K132Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | K132Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | K132Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | R2039H | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | R2039H | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | R2039H | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | R2039H | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | R2039H | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH2 | CdsStartSNV | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | CdsStartSNV | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | CdsStartSNV | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRD4 | K539K | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ALK | M233V | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M233V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | M233V | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | M233V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | M233V | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | M233V | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | M233V | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | M233V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | M233V | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | M233V | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | M233V | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | M233V | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | M233V | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M233V | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M233V | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | M233V | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | M233V | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | M233V | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | M233V | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | S215I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S215I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S215I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S215I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S215I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S215I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S215I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S215I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S215I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S215I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S215I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S215I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S215I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S215I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S215I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRAF | L745L | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | L745L | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | L745L | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | L745L | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| PML | R280L | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | R280L | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | R280L | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| MSH3 | splice_donor_variant | Complete Match | DNA-PKc inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH2 | A20G | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NOTCH1 | G2152G | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | G2152G | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | R79* | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | R79* | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| BRD4 | Q1298Q | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| BRCA2 | R2494* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | R2494* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | R2494* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | R2494* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | R2494* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | R2494* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | R2494* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | R2494* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | R2494* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | R2494* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | R2494* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | R2494* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | R2494* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | R2494* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| TP53 | S127F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S127F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S127F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S127F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S127F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S127F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S127F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S127F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S127F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S127F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S127F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S127F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S127F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S127F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S127F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF2 | Y144* | Complete Match | AR42 (HDAC inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | Y144* | Complete Match | AR42 (HDAC inhibitor) | Responsive | MEN | Early trials |
| NF2 | Y144* | Complete Match | HSP90 inhibitor | Responsive | MEN | Pre-clinical |
| NF2 | Y144* | Complete Match | Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) | Responsive | MEN | Pre-clinical |
| NF2 | Y144* | Complete Match | MTOR inhibitor | Responsive | MEN | Pre-clinical |
| NF2 | Y144* | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | NF, SCHW | Early trials |
| NF2 | Y144* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | SCHW | Early trials |
| NF2 | Y144* | Complete Match | Erlotinib (EGFR inhibitor) | No Responsive | SCHW | Early trials |
| NF2 | Y144* | Complete Match | FAK inhibitor | Responsive | OV | Pre-clinical |
| NF2 | Y144* | Complete Match | Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Case report |
| NF2 | Y144* | Complete Match | MEK inhibitor | Responsive | TH | Pre-clinical |
| NF2 | Y144* | Complete Match | PAK inhibitor | Responsive | SCHW, MEN | Pre-clinical |
| NF2 | Y144* | Complete Match | PDK1 inhibitor | Responsive | SCHW | Pre-clinical |
| NF2 | Y144* | Complete Match | FAK inhibitor | Responsive;Responsive | MESO | Early trials;Pre-clinical |
| NF2 | Y144* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | Y144* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | SCHW | Early trials |
| NF2 | Y144* | Different Alteration | FAK inhibitor | Responsive | OV | Pre-clinical |
| NF2 | Y144* | Different Alteration | MEK inhibitor | Responsive | TH | Pre-clinical |
| NF2 | Y144* | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | SCHW | Early trials |
| NF2 | Y144* | Different Alteration | Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) | Responsive | MEN | Pre-clinical |
| NF2 | Y144* | Different Alteration | PDK1 inhibitor | Responsive | SCHW | Pre-clinical |
| NF2 | Y144* | Different Alteration | PAK inhibitor | Responsive | SCHW, MEN | Pre-clinical |
| NF2 | Y144* | Different Alteration | AR42 (HDAC inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | Y144* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | SCHW | Pre-clinical |
| NF2 | Y144* | Different Alteration | Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Case report |
| NF2 | Y144* | Different Alteration | AR42 (HDAC inhibitor) | Responsive | MEN | Early trials |
| NF2 | Y144* | Different Alteration | FAK inhibitor | Responsive;Responsive | MESO | Early trials;Pre-clinical |
| NF2 | Y144* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | SCHW | Early trials |
| NF2 | Y144* | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | SCHW, NF | Early trials |
| NF2 | Y144* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SCHW | Early trials |
| NF2 | Y144* | Different Alteration | HSP90 inhibitor | Responsive | MEN | Pre-clinical |
| NF2 | Y144* | Different Alteration | MTOR inhibitor | Responsive | MEN | Pre-clinical |
| NOTCH2 | H1160R | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NOTCH1 | N685T | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | N685T | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | Q546* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q546* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q546* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q546* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PDGFRA | E715K | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| PML | T833T | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | T833T | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | T833T | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| HIF1A | R463* | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| CDKN2A | E69* | Complete Match | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | E69* | Complete Match | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | E69* | Complete Match | CDK4/6 inhibitor | Responsive | CM | Case report |
| CDKN2A | E69* | Complete Match | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | E69* | Different Alteration | CDK4/6 inhibitor | Responsive | CANCER, G | Pre-clinical |
| CDKN2A | E69* | Different Alteration | Ilorasertib (AURKA-VEGF inhibitor) | Responsive | CANCER | Early trials |
| CDKN2A | E69* | Different Alteration | PD1 inhibitor | Resistant | CM | Early trials |
| CDKN2A | E69* | Different Alteration | CDK4/6 inhibitor | Responsive | CM | Case report |
| MET | Y1252Y), MET MUT* (T200A | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NTRK3 | G233G | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | G233G | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | G233G | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NTRK1 | G89S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | G89S | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | G89S | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | G89S | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| JAK2 | T108A | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| NOTCH1 | Q1134R | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | Q1134R | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| FGFR3 | G65R | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | G65R | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | G65R | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| FGFR3 | K592K | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | K592K | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | K592K | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| TP53 | H179R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H179R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H179R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H179R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H179R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H179R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H179R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H179R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H179R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H179R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H179R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | L1012L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BCR | S459L | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | S459L | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | S459L | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | S459L | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | S459L | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | S459L | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Drug-Gene Interactions help
Druggable categories in the cohort
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|
Phenotype
Protein
Drug